A combination of Lactobacillus mali APS1 and dieting improved the efficacy of obesity treatment via manipulating gut microbiome in mice

Abstract

The difficulty of long-term management has produced a high rate of failure for obesity patients. Therefore, improving the efficacy of current obesity treatment is a significant goal. We hypothesized that combining a probiotic Lactobacillus mali APS1 intervention with dieting could improve the efficacy of obesity and hepatic steatosis treatment compared to dieting alone. Mice were fed a high-fat diet for 6 weeks and then treated with: saline + normal diet and APS1 + normal diet (NDAPS1) for 3 weeks. NDAPS1 accelerated body weight loss and reduced caloric intake and fat accumulation. The fecal microbiome showed that accelerating weight loss by NDAPS1 resulted in restoring intestinal microbiota toward a pre-obese state, with alteration of specific changes in the obesity-associated bacteria. APS1 manipulated the gut microbiome’s obesity-associated metabolites, followed by regulation of lipid metabolism, enhancement of energy expenditure and inhibition of appetite. The specific hepatic metabolites induced by the APS1-manipulated gut microbiome also contributed to the amelioration of hepatic steatosis. Our results highlighted a possible microbiome and metabolome that contributed to accelerating weight loss following treatment with a combination of APS1 and dieting and suggested that probiotics could serve as a potential therapy for modulating physiological function and downstream of the microbiota.

Inulin with different degrees of polymerization protects against diet-induced endotoxemia and inflammation in association with gut microbiota regulation in mice

“…A high-fat diet significantly increased the abundances of the Lachnospiraceae and Ruminococcaceae families (Fig. 5E), which are associated with obesity 14,15 .…”

Alginate oligosaccharide improves lipid metabolism and inflammation by modulating gut microbiota in high-fat diet fed mice

“…linked to the prevention of diet-induced obesity, liver steatosis, and insulin resistance in mice supplemented with a polyphenol-rich cranberry extract (Anhê et al 2015). Additionally, A. muciniphila was observed to be negatively associated with TC and LDL-C levels in postmenopausal women with obesity (Chen et al 2018). Although we have not directly established the causal association between A. muciniphila and the improved effects on lipid metabolism and inflammation in the present study, there has been an evidence that A. muciniphila intake improves high-fat diet-induced metabolic disorders, including fat mass gain, fasting hyperglycemia, metabolic endotoxemia, and inflammation in mice (Everard et al 2013).…”

Investigating the Mechanistic Differences of Obesity-Inducing Lactobacillus kefiranofaciens M1 and Anti-obesity Lactobacillus mali APS1 by Microbolomics and Metabolomics

“…After analysis by LEfSe and Spearman's correlations, two families, S24_7, and Christensenellaceae, biomarkers in the ND group, were negatively correlated with body weight gain and lipid weight. Both families have been reported to be associated with lean animals (Zhang et al, 2009;Serino et al, 2012;Lin et al, 2016a;Chen et al, 2018b;Peters et al, 2018), which were reduced in the HFDM1 and enriched in the HFDAPS1. The family Streptococcaceae, which was in abundance in obese animals (Peters et al, 2018), was abundant in the HFDM1 and reduced in the HFDAPS1.…”

“…The immunoregulatory effects of L. kefirnofaciens M1 involve upregulating the regulatory T (Treg) cell and inhibiting secretion of proinflammatory and inflammatory cytokines. L. mali APS1 demonstrated a beneficial effect on accelerating weight loss (Chen et al, 2018b) and on ameliorating hepatic steatosis (Chen et al, 2018a) in a murine model of diet-induced obesity. L. mali APS1 also possesses an anti-colitis effect.…”